| scholarly article | Q13442814 |
| P50 | author | Jinru Shia | Q39514846 |
| David H. Gultekin | Q51111933 | ||
| P2093 | author name string | L H Blumgart | |
| W R Jarnagin | |||
| Y Fong | |||
| L H Schwartz | |||
| N Kemeny | |||
| A Tse | |||
| M D'Angelica | |||
| M Gönen | |||
| R Dematteo | |||
| D Haviland | |||
| P2860 | cites work | New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada | Q27860904 |
| Arterial embolisation or chemoembolisation versus symptomatic treatment in patients with unresectable hepatocellular carcinoma: a randomised controlled trial | Q29617955 | ||
| Feasibility of using limited-population-based arterial input function for pharmacokinetic modeling of osteosarcoma dynamic contrast-enhanced MRI data | Q31153346 | ||
| Gemcitabine combined with oxaliplatin (GEMOX) in advanced biliary tract adenocarcinoma: a GERCOR study | Q33362191 | ||
| Combining gemcitabine and capecitabine in patients with advanced biliary cancer: a phase II trial | Q33365628 | ||
| Estimating kinetic parameters from dynamic contrast-enhanced T(1)-weighted MRI of a diffusable tracer: standardized quantities and symbols. | Q33744660 | ||
| Increasing incidence and mortality of primary intrahepatic cholangiocarcinoma in the United States | Q33949931 | ||
| Phase II study of erlotinib in patients with advanced biliary cancer | Q33997258 | ||
| An analysis of 412 cases of hepatocellular carcinoma at a Western center | Q34503813 | ||
| Hepatic arterial infusion of chemotherapy after resection of hepatic metastases from colorectal cancer | Q34506398 | ||
| Phase I trial of systemic oxaliplatin combination chemotherapy with hepatic arterial infusion in patients with unresectable liver metastases from colorectal cancer | Q34559194 | ||
| Technical complications and durability of hepatic artery infusion pumps for unresectable colorectal liver metastases: an institutional experience of 544 consecutive cases | Q36174825 | ||
| Dynamic contrast-enhanced magnetic resonance imaging as an imaging biomarker | Q36531396 | ||
| Imaging tumor vascular heterogeneity and angiogenesis using dynamic contrast-enhanced magnetic resonance imaging. | Q36851800 | ||
| Chemoembolization combined with radiofrequency ablation for patients with hepatocellular carcinoma larger than 3 cm: a randomized controlled trial | Q38391223 | ||
| A clinical-pharmacological evaluation of hepatic arterial infusions of 5-fluoro-2'-deoxyuridine and 5-fluorouracil | Q39863354 | ||
| Report of the 17th Nationwide Follow-up Survey of Primary Liver Cancer in Japan | Q40196680 | ||
| Magnetic resonance imaging measurements of the response of murine and human tumors to the vascular-targeting agent ZD6126. | Q40550062 | ||
| Reproducibility of dynamic contrast-enhanced MRI in human muscle and tumours: comparison of quantitative and semi-quantitative analysis. | Q40656791 | ||
| gamma-Hydroxybutyric acid and 5-fluorouracil, metabolites of UFT, inhibit the angiogenesis induced by vascular endothelial growth factor | Q40742848 | ||
| The long-term results of a randomized clinical trial of laparoscopy-assisted versus open surgery for colon cancer | Q42660407 | ||
| Expanding the use of magnetic resonance in the assessment of tumor response to therapy: workshop report | Q42665094 | ||
| Tumor microcirculation evaluated by dynamic magnetic resonance imaging predicts therapy outcome for primary rectal carcinoma | Q43566254 | ||
| Downstaging of hepatocellular carcinoma and liver metastases from colorectal cancer by selective intra-arterial chemotherapy | Q43949008 | ||
| Dynamic contrast-enhanced magnetic resonance imaging as a biomarker for the pharmacological response of PTK787/ZK 222584, an inhibitor of the vascular endothelial growth factor receptor tyrosine kinases, in patients with advanced colorectal cancer a | Q44601128 | ||
| Intrahepatic cholangiocarcinoma: rising frequency, improved survival, and determinants of outcome after resection | Q45424625 | ||
| Radiofrequency ablation of 231 unresectable hepatic tumors: indications, limitations, and complications | Q46347660 | ||
| Anti-angiogenic effect of 5-Fluorouracil-based drugs against human colon cancer xenografts | Q46638664 | ||
| Do cerebral blood volume and contrast transfer coefficient predict prognosis in human glioma? | Q48586356 | ||
| Measurement of the blood-brain barrier permeability and leakage space using dynamic MR imaging. 1. Fundamental concepts | Q48797418 | ||
| Prediction of chemotherapeutic response of colorectal liver metastases with dynamic gadolinium-DTPA-enhanced MRI and localized 19F MRS pharmacokinetic studies of 5-fluorouracil. | Q53518784 | ||
| Assessing changes in tumour vascular function using dynamic contrast-enhanced magnetic resonance imaging | Q62664246 | ||
| Treatment of unresectable primary liver cancer with intrahepatic fluorodeoxyuridine and mitomycin C through an implantable pump | Q67531478 | ||
| Randomized trial of hepatic arterial floxuridine, mitomycin, and carmustine versus floxuridine alone in previously treated patients with liver metastases from colorectal cancer | Q70543544 | ||
| Pharmacokinetics of GdDTPA/dimeglumine after intravenous injection into healthy volunteers | Q70685636 | ||
| Dynamic contrast enhanced magnetic resonance scanning as a predictor of response to accelerated radiotherapy for advanced head and neck cancer | Q73506317 | ||
| Rising incidence of hepatocellular carcinoma in the United States | Q74595692 | ||
| The theory and applications of the exchange of inert gas at the lungs and tissues | Q75726399 | ||
| Phase II study of sorafenib in patients with advanced hepatocellular carcinoma | Q80112177 | ||
| Measuring response in a post-RECIST world: from black and white to shades of grey | Q83190877 | ||
| P433 | issue | 9 | |
| P921 | main subject | liver cancer | Q623031 |
| magnetic resonance imaging | Q161238 | ||
| phase II clinical trial | Q42824440 | ||
| biomarker | Q864574 | ||
| chemotherapy | Q974135 | ||
| P304 | page(s) | 1589-1595 | |
| P577 | publication date | 2009-06-02 | |
| P1433 | published in | Annals of Oncology | Q326122 |
| P1476 | title | Regional chemotherapy for unresectable primary liver cancer: results of a phase II clinical trial and assessment of DCE-MRI as a biomarker of survival | |
| P478 | volume | 20 |
| Q50176693 | A phase I trial of arterial infusion chemotherapy with gemcitabine and 5-fluorouracil for unresectable biliary tract cancer. |
| Q39742586 | Accelerated Brain DCE-MRI Using Iterative Reconstruction With Total Generalized Variation Penalty for Quantitative Pharmacokinetic Analysis: A Feasibility Study |
| Q64070385 | Adjuvant hepatic arterial infusion pump chemotherapy and resection versus resection alone in patients with low-risk resectable colorectal liver metastases - the multicenter randomized controlled PUMP trial |
| Q48256960 | An efficient calculation method for pharmacokinetic parameters in brain permeability study using dynamic contrast-enhanced MRI. |
| Q35109141 | Antiangiogenic therapy for primary liver cancer: correlation of changes in dynamic contrast-enhanced magnetic resonance imaging with tissue hypoxia markers and clinical response |
| Q35082412 | Applications of Molecular Imaging |
| Q40621862 | Biphenotypic Primary Liver Carcinomas: Assessing Outcomes of Hepatic Directed Therapy. |
| Q35710375 | Cholangiocarcinoma: Correlation between Molecular Profiling and Imaging Phenotypes. |
| Q37296946 | Circulating Plasma Levels of MicroRNA-21 and MicroRNA-221 Are Potential Diagnostic Markers for Primary Intrahepatic Cholangiocarcinoma |
| Q36310736 | Clinical research of intraperitoneal implantation of sustained-release 5-fluorouracil in advanced colorectal cancer |
| Q37868455 | Contrast agents as a biological marker in magnetic resonance imaging of the liver: conventional and new approaches. |
| Q37660658 | DCE-MRI in hepatocellular carcinoma-clinical and therapeutic image biomarker. |
| Q31030824 | DCE-MRI of hepatocellular carcinoma: perfusion quantification with Tofts model versus shutter-speed model--initial experience |
| Q44004251 | Diffusion and perfusion MRI prediction of progression-free survival in patients with hepatocellular carcinoma treated with concurrent chemoradiotherapy |
| Q36747536 | Dual-input two-compartment pharmacokinetic model of dynamic contrast-enhanced magnetic resonance imaging in hepatocellular carcinoma |
| Q31119452 | Dynamic contrast enhanced MR imaging for evaluation of angiogenesis of hepatocellular nodules in liver cirrhosis in N-nitrosodiethylamine induced rat model |
| Q53190349 | Dynamic contrast enhanced-MRI for the detection of pathological complete response to neoadjuvant chemotherapy for locally advanced rectal cancer. |
| Q52943992 | Early perfusion changes within 1 week of systemic treatment measured by dynamic contrast-enhanced MRI may predict survival in patients with advanced hepatocellular carcinoma. |
| Q50053686 | Effects of harmaline on cell growth of human liver cancer through the p53/p21 and Fas/FasL signaling pathways |
| Q36093366 | Efficacy of hepatic arterial infusion chemotherapy in advanced hepatocellular carcinoma |
| Q57149355 | Efficacy of hepatic arterial infusion chemotherapy using 5-fluorouracil and systemic pegylated interferon α-2b for advanced intrahepatic cholangiocarcinoma |
| Q39746487 | Establishment and identification of the human multi-drug-resistant cholangiocarcinoma cell line QBC939/ADM. |
| Q38155097 | Floxuridine hepatic arterial infusion associated biliary toxicity is increased by concurrent administration of systemic bevacizumab |
| Q38314429 | Functional MRI and CT biomarkers in oncology |
| Q35698574 | HCC and angiogenesis: possible targets and future directions |
| Q42693724 | Hepatic arterial infusion with oxaliplatin and 5-FU/folinic acid for advanced biliary tract cancer: a phase II study |
| Q34089545 | Hepatocellular carcinoma: perfusion quantification with dynamic contrast-enhanced MRI |
| Q37729815 | Imaging ovarian cancer and peritoneal metastases--current and emerging techniques |
| Q38607490 | Intrahepatic chemotherapy for unresectable cholangiocarcinoma: review of literature and personal experience |
| Q35924971 | Intrahepatic cholangiocarcinoma: expert consensus statement. |
| Q38947234 | Locoregional Therapies of Cholangiocarcinoma |
| Q49474012 | Locoregional therapies in cholangiocarcinoma |
| Q64229411 | MRI assessment of hepatocellular carcinoma after locoregional therapy |
| Q37042355 | Magnetic resonance imaging biomarkers in hepatocellular carcinoma: association with response and circulating biomarkers after sunitinib therapy |
| Q26783874 | Management before hepatectomy for hepatocellular carcinoma with cirrhosis |
| Q33621522 | Management of unresectable intrahepatic cholangiocarcinoma: how do we decide among the various liver-directed treatments? |
| Q42872868 | Models of hepatocellular carcinoma and biomarker strategy |
| Q38707365 | Multimodality treatment of intrahepatic cholangiocarcinoma: A review |
| Q30364605 | Multiparametric MR Imaging in Abdominal Malignancies. |
| Q36419100 | Novel imaging biomarkers of response to transcatheter arterial chemoembolization in hepatocellular carcinoma patients |
| Q37869334 | Opportunities and pitfalls of cancer imaging in clinical trials |
| Q90593558 | Pemigatinib for previously treated, locally advanced or metastatic cholangiocarcinoma: a multicentre, open-label, phase 2 study |
| Q46442734 | Pharmacokinetic parameters from 3-Tesla DCE-MRI as surrogate biomarkers of antitumor effects of bevacizumab plus FOLFIRI in colorectal cancer with liver metastasis |
| Q37426851 | Predictive values of diffusion-weighted imaging and perfusion-weighted imaging in evaluating the efficacy of transcatheter arterial chemoembolization for hepatocellular carcinoma |
| Q43705438 | Prognostic aspects of DCE-MRI in recurrent rectal cancer |
| Q92582016 | Quantitative dynamic contrast-enhanced magnetic resonance imaging in a VX2 rabbit liver tumour model using different gadolinium-based contrast agents: comparison of DCE-MRI quantitative results between Magnevist and Eovist |
| Q30448049 | Recent Advances in CT and MR Imaging for Evaluation of Hepatocellular Carcinoma |
| Q40703610 | Recurrence Patterns and Disease-Free Survival after Resection of Intrahepatic Cholangiocarcinoma: Preoperative and Postoperative Prognostic Models |
| Q35892542 | Regional chemotherapy for unresectable intrahepatic cholangiocarcinoma: a potential role for dynamic magnetic resonance imaging as an imaging biomarker and a survival update from two prospective clinical trials. |
| Q34367593 | Review of treatment assessment using DCE-MRI in breast cancer radiation therapy |
| Q38539586 | Robotic liver resection for malignancy: Current status, oncologic outcomes, comparison to laparoscopy, and future applications |
| Q37990746 | Surgical management of proximal bile duct cancers |
| Q39656626 | Tamoxifen reverses the multi-drug-resistance of an established human cholangiocarcinoma cell line in combined chemotherapeutics |
| Q30274956 | The effect of preoperative chemotherapy treatment in surgically treated intrahepatic cholangiocarcinoma patients-A multi-institutional analysis |
| Q38778958 | The role of interventional radiology in the treatment of intrahepatic cholangiocarcinoma |
| Q34776912 | The role of magnetic resonance imaging biomarkers in clinical trials of treatment response in cancer |
| Q89619543 | The survival rate of hepatocellular carcinoma in Asian countries: a systematic review and meta-analysis |
| Q34630274 | Treating primary liver cancer with hepatic arterial infusion of floxuridine and dexamethasone: does the addition of systemic bevacizumab improve results? |
| Q36580868 | Tumor Vascular Permeability Pattern Is Associated With Complete Response in Immunocompetent Patients With Newly Diagnosed Primary Central Nervous System Lymphoma: Retrospective Cohort Study |
| Q36609503 | Unresectable intrahepatic cholangiocarcinoma: Systemic plus hepatic arterial infusion chemotherapy is associated with longer survival in comparison with systemic chemotherapy alone. |
| Q36072776 | Value of DCE-MRI and FDG-PET/CT in the prediction of response to preoperative chemotherapy with bevacizumab for colorectal liver metastases |
| Q28687190 | ¹⁸F-FDG PET metabolic parameters and MRI perfusion and diffusion parameters in hepatocellular carcinoma: a preliminary study |
Search more.